Europe Pneumococcal Vaccines Market Report 2024

Europe Pneumococcal Vaccines Market Report 2023 Market Size Split by Vaccine Type (Pneumococcal Polysaccharide Vaccines, Pneumococcal Conjugate Vaccines), Product Type (Pneumovax 23, Synflorix, Prevnar 13, Others), Sector (Public, Private), Distribution Channel (Pharmacies, Community clinics, Public Health agencies, Others)

Europe Pneumococcal Vaccines Market Report Description

Read a Detailed Qualitative analysis of the above report by requesting the free sample pages from Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Pneumococcal Vaccine Market

To sustain the increasing competition and attain new heights in providing healthcare services, companies are leveraging advancements in technology to innovate and launch new products to gain a competitive advantage. Companies are continuously investing in research and development activities to stay upgraded as per the changing consumer preferences, and market demand, and offer quality treatment options.

Top Companies Market Share in Europe Pneumococcal Vaccines Industry: (In no particular order of Rank)

• Pfizer Inc.
• GlaxoSmithKline plc
• Merck & Co. Inc.
• Serum Institute of India Pvt. Ltd
• Biological E. Limited
• Abbott
• Sanofi Pasteur SA
• Wyeth Pharmaceuticals LLC
• Walvax Biotechnology Co. Ltd.
• Sk Bioscience.
• Panacea Biotec Limited.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Europe Pneumococcal Vaccines Market Analysis

By Vaccine type, the market is dominated by Pneumococcal Conjugate Vaccines (PCV). These vaccines can protect children from Streptococcus pneumoniae, which is the most common cause of severe bacterial pneumonia among children. It is already been used in the national immunization program of 146 countries as of June 2020. PCV has demonstrated effectiveness in reducing the incidence and severity of pneumonia and other lower respiratory infections in children. PCVs are the vaccines that are generally recommended for infants younger than two years of age as Pneumococcal Polysaccharide Vaccines (PPSV) are comparatively less effective for this age group.

Note: The above Chart is for representative purposes and does not depict actual sales & statistics. You can request a free sample or purchase the full report access today!

Among all the product types, Prevenar 13 is reported to dominate the pneumococcal vaccine market. Prevenar 13 is a vaccine available as a suspension for injection that contains parts from 13 different types of the bacterium Streptococcus pneumoniae. It is normally used to protect children aged between six weeks and 17 years against invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae. This vaccine helps the body make its antibodies which protect against such diseases. As the name goes, Prevenar 13 is only capable of protecting against disease caused by thirteen strains of Streptococcus pneumoniae bacteria included in the vaccine. Additionally, as per studies, Prevenar 13 led to an increase in antibody production following booster vaccinations.

Note: The above Chart is for representative purposes and does not depict actual sales & statistics. You can request a free sample or purchase the full report access today!

Europe Pneumococcal Vaccines Sector Segment Analysis

• Public
• Private

Europe Pneumococcal Vaccines Distribution Channel Segment Analysis

Based on distribution channels, the market is reported to be dominated by public health agencies. They have the largest hold on the purchases of vaccines made by organizations like GAVI, WHO, UNICEF, and others. These organizations purchase vaccines in bulk quantities and distribute them across the geographies. 

GAVI-supported countries immunize more than 215 million children across 60 lower-income countries against pneumococcal disease in 2019.

In the same year, pneumococcal vaccine coverage in Gavi-supported countries was higher than the worldwide average of 49% in 2019.
(Source: https://www.gavi.org/types-support/vaccine-support/pneumococcal) 

• Pharmacies
• Community clinics
• Public Health agencies
• Others

Europe Pneumococcal Vaccines Country Analysis

In this section we have included market revenue, share, type, application and other segment analysis for each country level. Our team identifies and analyses potential risks associated with operating in each country, including rules and regulations, geopolitical risks, and other market-specific challenges. We estimate historical data and forecast future trends to understand the market's current situation in each country. This analysis helps key players to build strategies to strengthen their foothold in Europe Pneumococcal Vaccines market.

• United Kingdom
• France
• Germany
• Italy
• Russia
• Spain
• Sweden
• Denmark
• Netherlands
• Switzerland
• Belgium
• Rest of Europe

The Current Published report Editon on the website includes the following list of countries analysis whereas in case you looking to access any other country or states level data under Europe then please revert us to access the exclusive Europe Pneumococcal Vaccines industry report Edition.

The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!

The base years considered for all the estimations by analyzing trends and growth rate will help you gain an in-depth understanding of the conclusions provided in this report. This report also includes figures, graphs, pie charts, tables and bar graphs that explain the data analysis based on current trends at the country level as well as key regions. This research report also focuses on assessing factors such as profit, product price, capacity, production, supply demand market growth rate along with others to create a clear picture on the future prospects of this market.

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Bio :

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare indust...Read More

Author's Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Europe Pneumococcal Vaccines Market is witnessing significant growth in the near future.

In 2023, the Pneumococcal Polysaccharide Vaccines segment accounted for noticeable share of Europe Pneumococcal Vaccines Market and is projected to experience significant growth in the near future.

The Pneumovax 23 segment is expected to expand at the significant CAGR retaining position throughout the forecast period.

Some of the key companies Pfizer Inc. , Merck & Co. Inc. and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the market.

Frequently Asked Questions

What is Europe Pneumococcal Vaccines market size/share and growth rate?

Europe Pneumococcal Vaccinesmarket size and its growth rate has been provided in the report. The historical period included in the report is from 2019 to 2023, whereas, the report provides forecast data for the years 2023 to 2030. This will help you to in terms of market share, regional market share, country level market share to understand how the market has been performing in the past and how it is going to perform in the following years. Correspondingly, historical and forecast analysis comprises sales and revenue data of the Europe Pneumococcal Vaccinesmarket. Market size for UK, Europe, North America, Asia Pacific, Middle East & Africa is also included in the report.

What are the major factors affecting the Europe Pneumococcal Vaccines market?

The major factors affecting the Europe Pneumococcal Vaccines market in a positive, as well as negative perspective, have been provided with detailed analysis in the report. This segment has encompassed drivers, opportunities, and challenges faced by the industry. This will help you to understand the major factors impacting Europe Pneumococcal Vaccines market trends and develop your business strategy accordingly.

Who are the top manufacturers of Europe Pneumococcal Vaccines? List of Europe Pneumococcal Vaccines Companies and there market trend or market share?

Major manufacturers or list of Europe Pneumococcal Vaccines manufacturers 2023 involved in the market have been profiled in the report along with their business strategies, recent developments, SWOT analysis, business overview, and market Trend from the year 2018-2022. Europe Pneumococcal Vaccines Companies such as Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc., Serum Institute of India Pvt. Ltd, Biological E. Limited, Abbott, Sanofi Pasteur SA, Wyeth Pharmaceuticals LLC, Walvax Biotechnology Co. Ltd., Sk Bioscience., Panacea Biotec Limited. are part of the final deliverable document along with the same we can provide data for 2nd, 3rd, start-up level companies data and strategies as well. This will help you to understand the competitive analysis of the market and how other players are performing in the market. This detailed competitive analysis will help you to strategize your business accordingly and will keep you one step ahead. A quantitative and qualitative analysis of the main players in the Europe Pneumococcal Vaccines market is introduced, from the perspective of sales, revenue and price.

Which segments are covered under Europe Pneumococcal Vaccines market segments analysis?

Under Europe Pneumococcal Vaccines market segments analysis Vaccine Type, Product Type, Sector. It provides detailed insights on each type and application. Further, it provides which sub-segment is dominating the Europe Pneumococcal Vaccines market along with its reason. Additionally, the Europe Pneumococcal Vaccines market report will help you to analyze which sub-segment is fastest-growing during the forecast period.

What has been the impact of COVID-19 on the Europe Pneumococcal Vaccines market?

After the analysis of the complete market, the report has provided how the COVID-19 pandemic has affected the market. All the parameters have covered the overall impact of COVID -19 on the market value, market trend & growth of the market, and how the major players in the particular market are adopting these changes. This will help you to understand the overall optimistic, pessimistic, and neutral effects of the coronavirus pandemic on the Europe Pneumococcal Vaccines market.

How the Europe Pneumococcal Vaccines market performed till 2023 and how will it perform in the following years?

The Europe Pneumococcal Vaccines market has been analyzed thoroughly and has estimated the parameters which have affected the market in the historical period as well as how the market is going to perform in the following years. This will provide a complete market scenario and help you to strategize your next move accordingly to the Europe Pneumococcal Vaccines market Share.

Which region is expected to hold the highest market share in the Europe Pneumococcal Vaccines market?

The report gives an exhaustive investigation of the Europe Pneumococcal Vaccines market at country & regional levels, and provides an analysis of the industry trends in each of the regions, from sales, revenue, and consumption. It will help you to understand which region is dominating the market and is expected to grow significantly in the following years. The regional analysis will help you in strategizing the expansion of business.

What are the parameters used to analyze market position?

Europe Pneumococcal Vaccinesmarket report has provided PESTEL and Porter analysis to provide insightful information regarding the market scenario. It also provides market attractiveness analysis with an acknowledgment of various factors within the market, including growth rate and market size, as well as outside factors such as access to raw materials, competition, and industry capacity.

How to order Full Report or Sample pages of the Europe Pneumococcal Vaccines market?

The sample report for the Europe Pneumococcal Vaccines Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.